Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs?

Fig. 1

Sensitivity analyses: potential total savings of SQ HDM SLIT-tablet vs. HDM SCIT (Ontario and Quebec). Potential total savings according to total costs. Total cost of 3-year’s treatment are discounted with 1.5% as described in methods, except for the sensitivity analyses “0% discount rate” and “3% discount rate” where the parameter discount rate was changed to 0% or 3%, respectively. GP general practitioner, HDM SCIT house dust mite subcutaneous immunotherapy

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us